Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Biocon Biologics Limited, is an unlisted public company incorporated on 08 June, 2016. It is classified as a public limited company and is located in Bangalore, Karnataka. It's authorized share capital is INR 3,500.00 cr and the total paid-up capital is INR 1,758.31 cr.
Biocon Biologics Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has decreased by 170.56% over the previous year. At the same time, it's book networth has increased by 691.55%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
-11.43%
-170.56%
-617.79%
691.55%
-8.79%
209.36%
-3.84
-28.64
-23.96
-6.71
-22.58
-1.77
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(22)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
The Hongkong and Shanghai Banking Corporation Limited
No. of Loans: 2
Total Amount : 10,191.8 cr
Axis Trustee Services Limited
No. of Loans: 1
Total Amount : 7,947.9 cr
MUFG BANK LIMITED
No. of Loans: 1
Total Amount : 547.5 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Bobby Kanubhai Parikh
Shareholder
|
00019437 | 5 years |
| Nominee Director | Rajiv Malik | 00120557 | 2 years |
| Whole-time Director | Kiran Mazumdar Shaw | 00347229 | 9 years |
| Director | Nivruti Rai | 01353079 | 5 years |
| Director | Arun Suresh Chandavarkar
Shareholder
|
01596180 | 9 years |
| Director | Daniel Mark Bradbury | 06599933 | 5 years |
| Kmp | Akhilesh Kumar Nand | <HIDDEN> | 0 years |
| Director | Nicholas Robert Haggar | 08518863 | 1 years |
| Kmp | Kedar Upadhye | <HIDDEN> | 1 years |
| Director | Peter Baron Piot | 09015343 | 4 years |
| Director | Thomas Jason Roberts | 09337723 | 3 years |
| Kmp | Shreehas Pradeep Tambe | <HIDDEN> | 2 years |
| Managing Director | Shreehas Pradeep Tambe | 09796480 | 2 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| BMR BUSINESS SOLUTIONS PRIVATE LIMITED |
Active
|
8.5 L | 1 | Maharashtra |
| TAXAND ADVISORS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Delhi |
| BMR GLOBAL SERVICES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Delhi |
| INDOSTAR CAPITAL FINANCE LIMITED |
Active
|
136.1 Cr | 1 | Maharashtra |
| AVAANA CAPITAL ADVISORS LLP |
Active
|
13,333.0 | 1 | Maharashtra |
| INFOSYS LIMITED |
Active
|
2,076.1 Cr | 1 | Karnataka |
| BIOCON LIMITED |
Active
|
600.3 Cr | 3 | Karnataka |
| RELIANCE PETROLEUM LIMITED |
Amalgamated
|
4,500.0 Cr | 1 | Gujarat |
| MYLAN LABORATORIES LIMITED |
Active
|
48.7 Cr | 1 | Telangana |
| CLINIGENE INTERNATIONAL LIMITED |
Amalgamated
|
5.0 L | 1 | Karnataka |
| BIOCON BIOPHARMACEUTICALS LIMITED |
Amalgamated
|
17.6 Cr | 2 | Karnataka |
| CSEP RESEARCH FOUNDATION |
Active
|
1.0 L | 1 | Delhi |
| IMMUNEEL THERAPEUTICS PRIVATE LIMITED |
Active
|
4.6 L | 1 | Karnataka |
| NARAYANA VAISHNO DEVI SPECIALTY HOSPITALS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Karnataka |
| BIOCON RESEARCH LIMITED |
Active
|
5.0 L | 2 | Karnataka |
| BIOCON BIOSPHERE LIMITED |
Active
|
288.6 Cr | 1 | Karnataka |
| SCIENCE GALLERY BENGALURU |
Active
|
0.0 | 1 | Karnataka |
| BIOFUSION THERAPEUTICS LIMITED |
Active
|
5.0 L | 1 | Karnataka |
| GLENLOCH PROPERTIES LLP |
Active
|
1.0 L | 1 | Karnataka |
| MAZUMDAR SHAW MEDICAL FOUNDATION |
Active
|
1.0 L | 1 | Karnataka |
| NARAYANA HRUDAYALAYA LIMITED |
Active
|
204.4 Cr | 2 | Karnataka |
| BIOCON PHARMA LIMITED |
Active
|
887.1 Cr | 1 | Karnataka |
| BIOCON ACADEMY |
Active
|
5.0 L | 1 | Karnataka |
| TRENT LIMITED |
Active
|
35.5 Cr | 1 | Maharashtra |
| SYNGENE INTERNATIONAL LIMITED |
Active
|
402.5 Cr | 1 | Karnataka |
| INVEST INDIA |
Active
|
1.0 Cr | 1 | Delhi |
| MYNVAX PRIVATE LIMITED |
Active
|
6.0 L | 1 | Karnataka |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Biocon Biologics UK Limited | United Kingdom | - | - |
| Biocon SDN BHD | Malaysia | - | - |
| Biocon Biologics Healthcare SDN BHD | Malaysia | - | - |
| Biocon Biologics Inc | United States | - | - |
| Biocon Biologics Do Brasil Ltda | Brazil | - | - |
| Biocon Biologics FZ LLC | United Arab Emirates | - | - |
| Biosimilar Collaborations Ireland Limited | Ireland | - | - |
| Biosilars Newco Limited, UK | United Kingdom | - | - |
| Biocon Biologics Germany GmbH, Germany | Germany | - | - |
| Biocon Biologics Canada Inc, Canada | Canada | - | - |
| Biocon SDN BHD, Malaysia | Malaysia | - | - |
| Biocon Biologics Healthcare SDN BHD, Malaysia | Malaysia | - | - |
| Biocon Biologics Inc., USA | United States | - | - |
| Biosimilar Collaborations Ireland Limited, Ireland | Ireland | - | - |
| Biosimilars Newco Limited, UK | United Kingdom | - | - |
The incorporation date of BIOCON BIOLOGICS LIMITED is 08 June, 2016
The authorized share capital of BIOCON BIOLOGICS LIMITED is INR ₹ 3,500.0 Cr.
The paid-up capital of BIOCON BIOLOGICS LIMITED is INR ₹ 1,758.3 Cr.
The registered address of BIOCON BIOLOGICS LIMITED is Biocon House, Ground Floor, Tower-3, Semicon Park Electron ic City, Phase - II, Hosur Road NA Bengaluru Bangalore Karnataka - 560100
The CIN number of BIOCON BIOLOGICS LIMITED is U24119KA2016PLC093936.
Expand
Delete
Collapse
See
details
